[1] |
Park JW, Chen M, Colombo M, et al.Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study[J].Liver Int, 2015, 35(9): 2155-2166.DOI: 10.1111/liv.12818.
|
[2] |
Sung H, Ferlay J, Siegel RL, et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin, 2021, 71(3): 209-249.DOI: 10.3322/caac.21660.
|
[3] |
Kokudo N, Takemura N, Hasegawa K, et al.Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017(4th JSH-HCC guidelines) 2019 update[J].Hepatol Res, 2019, 49(10):1109-1113.DOI: 10.1111/hepr.13411.
|
[4] |
中华人民共和国国家卫生健康委员会.原发性肝癌诊疗指南(2022年版)[J].中国实用外科杂志, 2022, 42(3): 241-273.DOI: 10.19538/j.cjps.issn1005-2208.2022.03.01.Bureau of Medical Administration of National Health Commission of the People’s Republic of China.Standardization for diagnosis and treatment of hepatocellular carcinoma(2022 edition)[J].Chin J Pract Surg, 2022, 42(3): 241-273.DOI: 10.19538/j.cjps.issn1005-2208.2022.03.01.
|
[5] |
Mai Q, Mo Z, Shi F, et al.Lenvatinib plus hepatic arterial infusion of modified FOLFOX regime in patients with advanced hepatocellular carcinoma[J].J Clin Oncol, 2020, 38(15_suppl): e16603.DOI:10.1200/jco.2020.38.15_suppl.e16603.
|
[6] |
杨宇光, 唐辉, 谭志明, 等.仑伐替尼、PD-1抑制剂联合肝动脉栓塞灌注化疗治疗不可切除肝癌疗效[J/OL].中华肝脏外科手术学电子杂志, 2023, 12(1): 55-60.DOI: 10.3877/cma.j.issn.2095-3232.2023.01.011.Yang YG, Tang H, Tan ZM, et al.Efficacy of ranvartinib, PD-1 inhibitor combined with hepatic artery embolization and chemotherapy in the treatment of unresectable liver cancer[J/OL].Chin J Hepatic Surg (Electronic Edition), 2023, 12(1): 55-60.DOI: 10.3877/cma.j.issn.2095-3232.2023.01.011.
|
[7] |
梁雄, 伍楚蓉, 唐武兵, 等.介入治疗联合仑伐替尼及信迪利单抗治疗中晚期肝癌的近期疗效观察[J].现代肿瘤医学, 2023, 31(20):3812-3817.Liang X, Wu CR, Tang WB, et al.Short-term efficacy of interventional therapy combined with Lenvatinib and Sintlimab in the treatment of advanced hepatocellular carcinoma[J].J Mod Oncol, 2023, 31(20):3812-3817.
|
[8] |
Lencioni R, Llovet JM.Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J].Semin Liver Dis, 2010, 30(1): 52-60.DOI: 10.1055/s-0030-1247132.
|
[9] |
Zeng H, Zheng R, Guo Y, et al.Cancer survival in China, 2003-2005:a population-based study[J].Int J Cancer, 2015, 136(8): 1921-1930.DOI: 10.1002/ijc.29227.
|
[10] |
何传超, 肖治宇.晚期肝癌综合治疗模式与策略[J/OL].中华肝脏外科手术学电子杂志, 2023, 12(5): 486-489.DOI: 10.3877/cma.j.issn.2095-3232.2023.05.003.He CC, Xiao ZY.Comprehensive treatment model and strategy for advanced liver cancer[J/OL].Chin J Hepatic Surg (Electronic Edition), 2023, 12(5): 486-489.DOI: 10.3877/cma.j.issn.2095-3232.2023.05.003.
|
[11] |
刘晓侃, 张超杰, 赵辉.肝动脉灌注化疗及其联合治疗在中晚期肝细胞癌中的应用进展[J].肝脏, 2021, 26(12): 1411-1414.DOI:10.14000/j.cnki.issn.1008-1704.2021.12.031.Liu XK, Zhang CJ, Zhao H.Application progress of hepatic arterial infusion chemotherapy and its combination therapy in advanced hepatocellular carcinoma[J].Chin Hepatol, 2021, 26(12): 1411-1414.DOI: 10.14000/j.cnki.issn.1008-1704.2021.12.031.
|
[12] |
He MK, Le Y, Li QJ, et al.Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study[J].Chin J Cancer, 2017, 36(1): 83.DOI: 10.1186/s40880-017-0251-2.
|
[13] |
Zhao Y, Zhang YN, Wang KT, et al.Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy[J].Biochim Biophys Acta Rev Cancer, 2020, 1874(1): 188391.DOI:10.1016/j.bbcan.2020.188391.
|
[14] |
Li Q, Han J, Yang Y, et al.PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy[J].Front Immunol,2022, 13: 1070961.DOI: 10.3389/fimmu.2022.1070961.
|
[15] |
He M, Li Q, Zou R, et al.Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial[J].JAMA Oncol, 2019, 5(7): 953-960.DOI: 10.1001/jamaoncol.2019.0250.
|
[16] |
Long F, Chen S, Li R, et al.Efficacy and safety of HAIC alone vs.HAIC combined with lenvatinib for treatment of advanced hepatocellular carcinoma[J].Med Oncol, 2023, 40(5): 147.DOI: 10.1007/s12032-023-02012-x.
|
[17] |
于海东, 郭应兴, 雷振武, 等.肝动脉灌注化疗联合仑伐替尼治疗巴塞罗那临床肝癌B或C期肝细胞癌[J].中国介入影像与治疗学,2024, 21(2): 70-74.DOI: 10.13929/j.issn.1672-8475.2024.02.002.Yu HD, Guo YX, Lei ZW, et al.Hepatic artery infusion chemotherapy combined with lenvatinib for treating Barcelona clinic liver cancer stage B or C hepatocellular carcinoma[J].Chin J Interv Imag Ther,2024, 21(2): 70-74.DOI: 10.13929/j.issn.1672-8475.2024.02.002.
|
[18] |
Lai Z, He M, Bu X, et al.Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: a biomolecular exploratory, phase II trial[J].Eur J Cancer, 2022, 174: 68-77.DOI: 10.1016/j.ejca.2022.07.005.
|
[19] |
He MK, Liang RB, Zhao Y, et al.Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma[J].Ther Adv Med Oncol, 2021, 13:17588359211002720.DOI: 10.1177/17588359211002720.
|
[20] |
Mei J, Tang YH, Wei W, et al.Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma[J].Front Oncol,2021, 11: 618206.DOI: 10.3389/fonc.2021.618206.
|
[21] |
Zhu H, Shan Y, Ge K, et al.Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy[J].Cell Oncol, 2020, 43(6): 1203-1214.DOI: 10.1007/s13402-020-00552-2.
|
[22] |
Liu WM, Fowler DW, Smith P, et al.Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses[J].Br J Cancer, 2010, 102(1):115-123.DOI: 10.1038/sj.bjc.6605465.
|
[23] |
Mei J, Li SH, Li QJ, et al.Anti-PD-1 immunotherapy improves the efficacy of hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma[J].J Hepatocell Carcinoma, 2021, 8: 167-176.DOI: 10.2147/JHC.S298538.
|
[24] |
Deng H, Kan A, Lyu N, et al.Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits antitumor immunity and enhances programmed cell death-1 checkpoint blockade in hepatocellular carcinoma[J].Liver Cancer,2020, 9(3): 338-357.DOI: 10.1159/000505695.
|